Khamari et al. reported that sulfasalazine, an inhibitor of xCT, approved for the treatment of inflammatory bowel disease, is also able to delay the growth of BRAFi-resistant melanoma in vitro (Table 1) (235). The gene discussed is SLC7A11; the disease is melanoma.